miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute...

Area of Science:

• Pharmacogenomics
• Molecular Biology
• Cardiovascular Medicine

Background:

• Clopidogrel is crucial for acute coronary syndrome (ACS) patients.
• Bleeding is a significant adverse event, but its genetic basis is unclear.
• CYP2C19 variants are known to affect clopidogrel efficacy, but other genetic factors may influence bleeding risk.

Purpose of the Study:

• To investigate the role of CYP2C19*2, CYP2C19*3, and 10 miRNA polymorphisms in clopidogrel-related bleeding in Chinese ACS patients.
• To identify specific genetic markers associated with increased bleeding risk.
• To elucidate the molecular mechanism linking genetic variations to bleeding events.

Main Methods:

• Genotyping of CYP2C19*2, CYP2C19*3, and 10 miRNA polymorphisms in Chinese ACS patients.
• Statistical analysis to assess the association between polymorphisms and bleeding risk.
• Dual luciferase assay to confirm the interaction between miR-6076 and P2RY12 mRNA.

Main Results:

• The miR-6076 rs1463411 G polymorphism was significantly associated with increased bleeding risk (P < 0.001).
• The rs1463411 GT + GG genotype showed a 6.09-fold increased risk of bleeding (adjusted OR, 6.09; 95% CI, 1.09-34.0; P < 0.001).
• miR-6076 directly targets P2RY12 mRNA, reducing its expression, with the G allele further decreasing P2RY12 levels.

Conclusions:

• The miR-6076 rs1463411 T/G polymorphism influences P2RY12 expression, potentially increasing bleeding risk in ACS patients on clopidogrel.
• This finding highlights miR-6076 as a potential biomarker for predicting clopidogrel-associated bleeding.
• Further research is warranted to validate these findings and explore therapeutic implications.